Loading…
Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study
The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to coll...
Saved in:
Published in: | International Journal of Endocrinology 2016-01, Vol.2016 (2016), p.401-405-146 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143 |
---|---|
cites | cdi_FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143 |
container_end_page | 405-146 |
container_issue | 2016 |
container_start_page | 401 |
container_title | International Journal of Endocrinology |
container_volume | 2016 |
creator | Regidor, Pedro-Antonio Schindler, Adolf Eduard |
description | The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to collect data on ovulation and pregnancy rates in PCOS patients with infertility. In this observational study, 3602 infertile women used myoinositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day. In a subgroup of 32 patients, hormonal values for testosterone, free testosterone, and progesterone were analyzed before and after 12 weeks of treatment. The mean time of use was 10.2 weeks. During this time 70% of these women had a restored ovulation, and 545 pregnancies were obtained. This means a pregnancy rate of 15.1% of all the myoinositol and folic acid users. In 19 cases a concomitant medication with clomiphene or dexamethasone was used. One twin pregnancy was documented. Testosterone levels changed from 96.6 ng/ml to 43.3 ng/ml and progesterone from 2.1 ng/ml to 12.3 ng/ml ( p < 0.05 ) after 12 weeks of treatment. No relevant side effects were present among the patients. This study could show that a new treatment option for patients with a PCOS and infertility is available. The achieved pregnancy rates are at least in an equivalent or even superior range than those reported by the use of metformin. |
doi_str_mv | 10.1155/2016/9537632 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e722859319ee4d1a9d6a724f86898f71</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A509160550</galeid><airiti_id>P20160919002_201612_201703160009_201703160009_401_405_146</airiti_id><doaj_id>oai_doaj_org_article_e722859319ee4d1a9d6a724f86898f71</doaj_id><sourcerecordid>A509160550</sourcerecordid><originalsourceid>FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143</originalsourceid><addsrcrecordid>eNqNkl1rFDEUhgdRbK3eeS0BQQTd9iQz-fJCWIrWQqWFVrwM2ZmTbspssk1mKv33Zndr2xUvZBjy9eTNOec9VfWawj6lnB8woOJA81qKmj2pdqlQcqLqhj-9n9dyp3qR8xWAEALo82qHSdEwpuVuNX6_jT7E7IfYE5uJJefWIbGhI9N-wBTs4G-QTJfLFG07Jz6QYY7kIqEdFhgGEh05Dg7T4HskZ4en5-RnLAefyJQcYVrYQE5nGdNN0YnB9uR8GLvbl9UzZ_uMr-7GverH1y8Xh98mJ6dHx4fTk4mVshkmM5hJSZlyTQNatR1wpuq25pqjoAiOccmcAnDQNdp1ra2psrpk3WnKGG3qvep4o9tFe2WWyS9sujXRerPeiOnS2BJ526NByZjiuqYasemo1Z2wkjVOCaWVk7Rofd5oLcfZAru2JJ9svyW6fRL83FzGG8Oh-FQC36ve3wmkeD1iHszC5xb73gaMYzZUMSqVBloX9O1f6FUcixd9NqwBKQQtBj5Ql7Yk4IOL5d12JWqmHEodgHMo1P4_qPJ1uPBtDOiKc9sX3j26MEfbD_Mc-3FlYN4GP27ANsWcE7r7YlAwq940q940d71Z8DePC3gP_2nGAnzYAHMfOvvL_6ccFgadfaAplPhW4Z1tAOuTH_xDCc9WOiULDcDWmnQ9SKjLNoDeXjRAy88NbUT9G6D6BlI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2407661764</pqid></control><display><type>article</type><title>Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study</title><source>Publicly Available Content Database</source><source>Wiley_OA刊</source><source>PubMed</source><creator>Regidor, Pedro-Antonio ; Schindler, Adolf Eduard</creator><contributor>Unfer, Vittorio ; Vittorio Unfer</contributor><creatorcontrib>Regidor, Pedro-Antonio ; Schindler, Adolf Eduard ; Unfer, Vittorio ; Vittorio Unfer</creatorcontrib><description>The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to collect data on ovulation and pregnancy rates in PCOS patients with infertility. In this observational study, 3602 infertile women used myoinositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day. In a subgroup of 32 patients, hormonal values for testosterone, free testosterone, and progesterone were analyzed before and after 12 weeks of treatment. The mean time of use was 10.2 weeks. During this time 70% of these women had a restored ovulation, and 545 pregnancies were obtained. This means a pregnancy rate of 15.1% of all the myoinositol and folic acid users. In 19 cases a concomitant medication with clomiphene or dexamethasone was used. One twin pregnancy was documented. Testosterone levels changed from 96.6 ng/ml to 43.3 ng/ml and progesterone from 2.1 ng/ml to 12.3 ng/ml ( p < 0.05 ) after 12 weeks of treatment. No relevant side effects were present among the patients. This study could show that a new treatment option for patients with a PCOS and infertility is available. The achieved pregnancy rates are at least in an equivalent or even superior range than those reported by the use of metformin.</description><identifier>ISSN: 1687-8337</identifier><identifier>EISSN: 1687-8345</identifier><identifier>DOI: 10.1155/2016/9537632</identifier><identifier>PMID: 27642297</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Acids ; Androgens ; Bioavailability ; Care and treatment ; Causes of ; Complications and side effects ; Dosage and administration ; Endocrinology ; Glucose ; Gynecology ; Infertility ; Infertility, Female ; Inositol ; Insulin resistance ; Menstruation ; Observational studies ; Ovulation ; Patient outcomes ; Pregnancy ; Questionnaires ; Stein-Leventhal syndrome ; Studies ; Testosterone ; Vitamin B</subject><ispartof>International Journal of Endocrinology, 2016-01, Vol.2016 (2016), p.401-405-146</ispartof><rights>Copyright © 2016 Pedro-Antonio Regidor and Adolf Eduard Schindler.</rights><rights>COPYRIGHT 2016 John Wiley & Sons, Inc.</rights><rights>Copyright © 2016 Pedro-Antonio Regidor and Adolf Eduard Schindler. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2016 P.-A. Regidor and A. E. Schindler. 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143</citedby><cites>FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143</cites><orcidid>0000-0002-9551-2847</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2407661764/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2407661764?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25751,27922,27923,37010,37011,44588,53789,53791,74896</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27642297$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Unfer, Vittorio</contributor><contributor>Vittorio Unfer</contributor><creatorcontrib>Regidor, Pedro-Antonio</creatorcontrib><creatorcontrib>Schindler, Adolf Eduard</creatorcontrib><title>Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study</title><title>International Journal of Endocrinology</title><addtitle>Int J Endocrinol</addtitle><description>The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to collect data on ovulation and pregnancy rates in PCOS patients with infertility. In this observational study, 3602 infertile women used myoinositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day. In a subgroup of 32 patients, hormonal values for testosterone, free testosterone, and progesterone were analyzed before and after 12 weeks of treatment. The mean time of use was 10.2 weeks. During this time 70% of these women had a restored ovulation, and 545 pregnancies were obtained. This means a pregnancy rate of 15.1% of all the myoinositol and folic acid users. In 19 cases a concomitant medication with clomiphene or dexamethasone was used. One twin pregnancy was documented. Testosterone levels changed from 96.6 ng/ml to 43.3 ng/ml and progesterone from 2.1 ng/ml to 12.3 ng/ml ( p < 0.05 ) after 12 weeks of treatment. No relevant side effects were present among the patients. This study could show that a new treatment option for patients with a PCOS and infertility is available. The achieved pregnancy rates are at least in an equivalent or even superior range than those reported by the use of metformin.</description><subject>Acids</subject><subject>Androgens</subject><subject>Bioavailability</subject><subject>Care and treatment</subject><subject>Causes of</subject><subject>Complications and side effects</subject><subject>Dosage and administration</subject><subject>Endocrinology</subject><subject>Glucose</subject><subject>Gynecology</subject><subject>Infertility</subject><subject>Infertility, Female</subject><subject>Inositol</subject><subject>Insulin resistance</subject><subject>Menstruation</subject><subject>Observational studies</subject><subject>Ovulation</subject><subject>Patient outcomes</subject><subject>Pregnancy</subject><subject>Questionnaires</subject><subject>Stein-Leventhal syndrome</subject><subject>Studies</subject><subject>Testosterone</subject><subject>Vitamin B</subject><issn>1687-8337</issn><issn>1687-8345</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl1rFDEUhgdRbK3eeS0BQQTd9iQz-fJCWIrWQqWFVrwM2ZmTbspssk1mKv33Zndr2xUvZBjy9eTNOec9VfWawj6lnB8woOJA81qKmj2pdqlQcqLqhj-9n9dyp3qR8xWAEALo82qHSdEwpuVuNX6_jT7E7IfYE5uJJefWIbGhI9N-wBTs4G-QTJfLFG07Jz6QYY7kIqEdFhgGEh05Dg7T4HskZ4en5-RnLAefyJQcYVrYQE5nGdNN0YnB9uR8GLvbl9UzZ_uMr-7GverH1y8Xh98mJ6dHx4fTk4mVshkmM5hJSZlyTQNatR1wpuq25pqjoAiOccmcAnDQNdp1ra2psrpk3WnKGG3qvep4o9tFe2WWyS9sujXRerPeiOnS2BJ526NByZjiuqYasemo1Z2wkjVOCaWVk7Rofd5oLcfZAru2JJ9svyW6fRL83FzGG8Oh-FQC36ve3wmkeD1iHszC5xb73gaMYzZUMSqVBloX9O1f6FUcixd9NqwBKQQtBj5Ql7Yk4IOL5d12JWqmHEodgHMo1P4_qPJ1uPBtDOiKc9sX3j26MEfbD_Mc-3FlYN4GP27ANsWcE7r7YlAwq940q940d71Z8DePC3gP_2nGAnzYAHMfOvvL_6ccFgadfaAplPhW4Z1tAOuTH_xDCc9WOiULDcDWmnQ9SKjLNoDeXjRAy88NbUT9G6D6BlI</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Regidor, Pedro-Antonio</creator><creator>Schindler, Adolf Eduard</creator><general>Hindawi Limiteds</general><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9551-2847</orcidid></search><sort><creationdate>20160101</creationdate><title>Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study</title><author>Regidor, Pedro-Antonio ; Schindler, Adolf Eduard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acids</topic><topic>Androgens</topic><topic>Bioavailability</topic><topic>Care and treatment</topic><topic>Causes of</topic><topic>Complications and side effects</topic><topic>Dosage and administration</topic><topic>Endocrinology</topic><topic>Glucose</topic><topic>Gynecology</topic><topic>Infertility</topic><topic>Infertility, Female</topic><topic>Inositol</topic><topic>Insulin resistance</topic><topic>Menstruation</topic><topic>Observational studies</topic><topic>Ovulation</topic><topic>Patient outcomes</topic><topic>Pregnancy</topic><topic>Questionnaires</topic><topic>Stein-Leventhal syndrome</topic><topic>Studies</topic><topic>Testosterone</topic><topic>Vitamin B</topic><toplevel>online_resources</toplevel><creatorcontrib>Regidor, Pedro-Antonio</creatorcontrib><creatorcontrib>Schindler, Adolf Eduard</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International Journal of Endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Regidor, Pedro-Antonio</au><au>Schindler, Adolf Eduard</au><au>Unfer, Vittorio</au><au>Vittorio Unfer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study</atitle><jtitle>International Journal of Endocrinology</jtitle><addtitle>Int J Endocrinol</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>2016</volume><issue>2016</issue><spage>401</spage><epage>405-146</epage><pages>401-405-146</pages><issn>1687-8337</issn><eissn>1687-8345</eissn><abstract>The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to collect data on ovulation and pregnancy rates in PCOS patients with infertility. In this observational study, 3602 infertile women used myoinositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day. In a subgroup of 32 patients, hormonal values for testosterone, free testosterone, and progesterone were analyzed before and after 12 weeks of treatment. The mean time of use was 10.2 weeks. During this time 70% of these women had a restored ovulation, and 545 pregnancies were obtained. This means a pregnancy rate of 15.1% of all the myoinositol and folic acid users. In 19 cases a concomitant medication with clomiphene or dexamethasone was used. One twin pregnancy was documented. Testosterone levels changed from 96.6 ng/ml to 43.3 ng/ml and progesterone from 2.1 ng/ml to 12.3 ng/ml ( p < 0.05 ) after 12 weeks of treatment. No relevant side effects were present among the patients. This study could show that a new treatment option for patients with a PCOS and infertility is available. The achieved pregnancy rates are at least in an equivalent or even superior range than those reported by the use of metformin.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>27642297</pmid><doi>10.1155/2016/9537632</doi><orcidid>https://orcid.org/0000-0002-9551-2847</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1687-8337 |
ispartof | International Journal of Endocrinology, 2016-01, Vol.2016 (2016), p.401-405-146 |
issn | 1687-8337 1687-8345 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_e722859319ee4d1a9d6a724f86898f71 |
source | Publicly Available Content Database; Wiley_OA刊; PubMed |
subjects | Acids Androgens Bioavailability Care and treatment Causes of Complications and side effects Dosage and administration Endocrinology Glucose Gynecology Infertility Infertility, Female Inositol Insulin resistance Menstruation Observational studies Ovulation Patient outcomes Pregnancy Questionnaires Stein-Leventhal syndrome Studies Testosterone Vitamin B |
title | Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A03%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Myoinositol%20as%20a%20Safe%20and%20Alternative%20Approach%20in%20the%20Treatment%20of%20Infertile%20PCOS%20Women:%20A%20German%20Observational%20Study&rft.jtitle=International%20Journal%20of%20Endocrinology&rft.au=Regidor,%20Pedro-Antonio&rft.date=2016-01-01&rft.volume=2016&rft.issue=2016&rft.spage=401&rft.epage=405-146&rft.pages=401-405-146&rft.issn=1687-8337&rft.eissn=1687-8345&rft_id=info:doi/10.1155/2016/9537632&rft_dat=%3Cgale_doaj_%3EA509160550%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2407661764&rft_id=info:pmid/27642297&rft_galeid=A509160550&rft_airiti_id=P20160919002_201612_201703160009_201703160009_401_405_146&rfr_iscdi=true |